The non-invasive cancer diagnostics market is estimated to be worth around USD 20.1 billion by 2030,
Roots Analysis is pleased to announce the publication of its recent study, titled, "Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes.
By: Roots Analysis
§ A detailed review of the overall landscape of the non-invasive cancer diagnostics market.
§ An analysis of the various partnerships pertaining to non-invasive cancer diagnostics, which have been established between 2016 and 2019.
§ An analysis of the investments made in companies engaged in the development of non-invasive cancer diagnostics.
§ An analysis of the initiatives of big pharma players.
§ A detailed acquisition target analysis.
§ Elaborate profiles of the key players engaged in this domain.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Type of Tumor Marker
§ Diagnosis / Early Diagnosis
§ Patient Monitoring
§ Recurrence Monitoring
§ Target Cancer Indication
§ Breast Cancer
§ Lung Cancer
§ Colorectal Cancer
§ Prostate Cancer
§ Bladder Cancer
§ Gastric Cancer
§ Pancreatic Cancer
§ Ovarian Cancer
§ End Users
§ Research Institutes
§ Key Geographical Regions
§ North America
§ Rest of the World
Key companies covered in the report (https://www.rootsanalysis.com/
§ Amoy Diagnostics
§ HaploX Biotechnology
§ Swift Biosciences
§ Sysmex Inostics
§ Thermo Fisher Scientific
For more information, please click on the following link:
Other recent offerings
1. Companion Diagnostics Market (2nd Edition), 2019-2030
2. Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030
3. Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030
Roots Analysis Private Limited
+1 (415) 800 3415